Treatment of Iatrogenic Kaposi Sarcoma in Organ Transplant Recipients
Iatrogenic Kaposi sarcoma arises as a direct consequence of immunosuppressive therapy. In organ transplant recipients, where ongoing immunosuppression is required, this creates a specific clinical challenge that calls for a structured, evidence-based response.
Clinical Situation
This protocol addresses Kaposi sarcoma occurring in patients on immunosuppressive regimens — in particular, organ transplant recipients maintained on calcineurin inhibitor-based therapy.
Treatment Approach
Management centres on modification of the patient's existing immunosuppressive regimen. The full protocol specifies which adjustments apply and in what order.
Treatment Goal
Regression of Kaposi's sarcoma lesions — with the most favourable outcomes expected in early, non-aggressive presentations.
References
DOI: 10.1111/ddg.14788
- When iatrogenic KS occurs, consideration should be given to discontinuing, reducing, or reversing immunosuppressive therapy.
- Reducing the intensity of immunosuppression or switching immunosuppressants to mTOR inhibitors, such as sirolimus or everolimus, are cornerstones of treatment.
- Regression of KS has been reported after switching from calcineurin inhibitors to sirolimus by restoring effector and memory T-cell immune activity against HHV-8.
- Spontaneous tumor regression may occur after cessation of immunosuppression, especially in early, non-aggressive stages.